You are currently browsing the archives for 21 February 2015.
Displaying 1 entry.

With this vaccine.

‘With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients. ‘the study, which involved the National Cancer Institute, Gulley and his team of 26 patients, all of them heavily pretreated, with 21 patients who have at least three prior chemotherapy treatments, finances and called them the monthly vaccinations with PANVAC vaccine obtained that transgenes containing MUC-1, CEA and three T-cell costimulatory molecules.

In 12 breast cancer patients , the team formed a median time to disease progression of 2.5 months and a median survival of 13.7 months. – had stable disease. The average time to progression in the 14 patients with ovarian cancer were two months and the median survival time of 15 months.